NASDAQ:VRCA Verrica Pharmaceuticals - VRCA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.50 -0.14 (-2.11%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$6.37▼$6.7350-Day Range$4.15▼$8.5152-Week Range$1.77▼$9.22Volume156,837 shsAverage Volume185,587 shsMarket Capitalization$272.03 millionP/E RatioN/ADividend YieldN/APrice Target$10.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Verrica Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside64.1% Upside$10.67 Price TargetShort InterestHealthy1.22% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment1.03Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.95) to ($0.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector356th out of 1,004 stocksPharmaceutical Preparations Industry161st out of 489 stocks 3.4 Analyst's Opinion Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.67, Verrica Pharmaceuticals has a forecasted upside of 64.1% from its current price of $6.50.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.22% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently increased by 24.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVerrica Pharmaceuticals has received a 75.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Verrica Pharmaceuticals is -0.67. Previous Next 2.8 News and Social Media Coverage News SentimentVerrica Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for VRCA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders43.50% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.94% of the stock of Verrica Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -7.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -7.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 6.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verrica Pharmaceuticals (NASDAQ:VRCA) StockVerrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.Read More Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VRCA Stock News HeadlinesMarch 30, 2023 | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest UpdateMarch 25, 2023 | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Forecasted to Post Q1 2023 Earnings of ($0.20) Per ShareMarch 31, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 24, 2023 | americanbankingnews.comAnalysts Issue Forecasts for Verrica Pharmaceuticals Inc.'s Q2 2023 Earnings (NASDAQ:VRCA)March 22, 2023 | americanbankingnews.comVerrica Pharmaceuticals (NASDAQ:VRCA) Coverage Initiated by Analysts at Jefferies Financial GroupMarch 21, 2023 | bizjournals.comNovan searches for capital to see company through FDA processMarch 6, 2023 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial ResultsMarch 6, 2023 | finance.yahoo.comVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial ResultsMarch 31, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 2, 2023 | msn.comNOVN: NDA SubmittedMarch 1, 2023 | finance.yahoo.comVerrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care ConferenceFebruary 27, 2023 | finance.yahoo.comVerrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum ContagiosumFebruary 22, 2023 | finance.yahoo.comVerrica Pharmaceuticals expects $32.5M from the sale of stock and warrantsFebruary 21, 2023 | marketwatch.comVerrica Prices Offering With Expected Proceeds of $32.5MFebruary 21, 2023 | finance.yahoo.comVerrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsJanuary 24, 2023 | baystreet.caVerrica Flat on Forwarding NDA to FDAJanuary 24, 2023 | bizjournals.comVerrica Pharmaceuticals makes fourth attempt at FDA approval for its lead new drug candidateJanuary 24, 2023 | msn.comVerrica refiles seeking FDA approval of viral skin disease drug VP-102January 24, 2023 | finance.yahoo.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have significant skin in the game with 40% ownershipJanuary 24, 2023 | finance.yahoo.comVerrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumJanuary 4, 2023 | finance.yahoo.comVerrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma SolutionsJanuary 1, 2023 | finance.yahoo.comBullish insiders bet US$11m on Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)December 12, 2022 | finance.yahoo.comWe're Not Very Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn RateDecember 2, 2022 | msn.comVerrica Pharmaceuticals's Return On Capital Employed OverviewNovember 26, 2022 | finance.yahoo.comInvestors in Verrica Pharmaceuticals (NASDAQ:VRCA) have unfortunately lost 83% over the last three yearsNovember 7, 2022 | finance.yahoo.comVerrica Pharmaceuticals Reports Third Quarter 2022 Financial ResultsOctober 16, 2022 | reuters.comVerrica Pharmaceuticals IncSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VRCA Company Calendar Last Earnings3/06/2023Today3/31/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRCA CUSIPN/A CIK1660334 Webwww.verrica.com Phone(434) 453-3300FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.67 High Stock Price Forecast$11.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+64.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,490,000.00 Net Margins-271.11% Pretax Margin-271.11% Return on Equity-70.83% Return on Assets-39.16% Debt Debt-to-Equity RatioN/A Current Ratio11.31 Quick Ratio11.31 Sales & Book Value Annual Sales$9.03 million Price / Sales30.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book6.70Miscellaneous Outstanding Shares41,850,000Free Float23,646,000Market Cap$272.03 million OptionableNot Optionable Beta2.03 Key ExecutivesTed WhitePresident, Chief Executive Officer & DirectorTerence KohlerChief Financial OfficerGary GoldenbergChief Medical OfficerEugene ScavolaExecutive Vice President-Technical OperationsChristopher G. HayesSecretary, Chief Legal & Compliance OfficerKey CompetitorsVaxxinityNASDAQ:VAXXCara TherapeuticsNASDAQ:CARAPepGenNASDAQ:PEPGAtea PharmaceuticalsNASDAQ:AVIROmerosNASDAQ:OMERView All CompetitorsInsiders & InstitutionsMillennium Management LLCBought 131,372 shares on 2/15/2023Ownership: 0.500%Jane Street Group LLCBought 18,052 shares on 2/15/2023Ownership: 0.044%Morgan StanleySold 29,106 shares on 2/15/2023Ownership: 0.032%Two Sigma Investments LPBought 1,927 shares on 2/14/2023Ownership: 0.124%Susquehanna International Group LLPBought 10,284 shares on 2/14/2023Ownership: 0.110%View All Insider TransactionsView All Institutional Transactions VRCA Stock - Frequently Asked Questions Should I buy or sell Verrica Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRCA shares. View VRCA analyst ratings or view top-rated stocks. What is Verrica Pharmaceuticals' stock price forecast for 2023? 4 Wall Street analysts have issued 1 year target prices for Verrica Pharmaceuticals' shares. Their VRCA share price forecasts range from $10.00 to $11.00. On average, they anticipate the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price. View analysts price targets for VRCA or view top-rated stocks among Wall Street analysts. How have VRCA shares performed in 2023? Verrica Pharmaceuticals' stock was trading at $2.75 at the start of the year. Since then, VRCA stock has increased by 136.4% and is now trading at $6.50. View the best growth stocks for 2023 here. Are investors shorting Verrica Pharmaceuticals? Verrica Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 301,600 shares, an increase of 24.8% from the February 28th total of 241,600 shares. Based on an average trading volume of 180,200 shares, the short-interest ratio is currently 1.7 days. Approximately 1.2% of the company's shares are short sold. View Verrica Pharmaceuticals' Short Interest. When is Verrica Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our VRCA earnings forecast. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) posted its quarterly earnings data on Monday, March, 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The company had revenue of $0.07 million for the quarter. Verrica Pharmaceuticals had a negative net margin of 271.11% and a negative trailing twelve-month return on equity of 70.83%. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI) and Aeterna Zentaris (AEZS). When did Verrica Pharmaceuticals IPO? (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO. What is Verrica Pharmaceuticals' stock symbol? Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA." Who are Verrica Pharmaceuticals' major shareholders? Verrica Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (2.70%), Millennium Management LLC (0.50%), Geode Capital Management LLC (0.40%), Renaissance Technologies LLC (0.38%), Conning Inc. (0.31%) and Fosun International Ltd (0.31%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, John A Stalfort III, Paul B Manning, Paul B Manning, Perceptive Advisors Llc and Ted White. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verrica Pharmaceuticals' stock price today? One share of VRCA stock can currently be purchased for approximately $6.50. How much money does Verrica Pharmaceuticals make? Verrica Pharmaceuticals (NASDAQ:VRCA) has a market capitalization of $272.03 million and generates $9.03 million in revenue each year. The company earns $-24,490,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. How can I contact Verrica Pharmaceuticals? Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The official website for the company is www.verrica.com. The company can be reached via phone at (434) 453-3300 or via email at info@verrica.com. This page (NASDAQ:VRCA) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.